POPULARITY
In the first segment, Dr. Alex Menze speaks with Prof. Antonio Belli about the role of salivary small non-coding RNAs in the diagnosis of sport-related concussion. In the second part of the podcast, Dr. David Lapides talks to Dr. Linda D’Antona about the utility of brain MRI and ophthalmic biomarkers for the prediction of intracranial hypertension.
In the first segment, Dr. Stacey Clardy speaks with Dr. Petra Ijäs about the incidence of stroke during pregnancy or puerperium in Finland from 1987-2016. In the second part of the podcast, Dr. David Lapides talks with Dr. Emma Ciafaloni about management of pregnancy in myasthenia gravis.
In the first segment, Dr. Jeff Burns speaks with Prof. Maria Eriksdotter about whether Cholinesterase inhibitors are associated with slower cognitive decline and decreased mortality risk. In the second part of the podcast, Dr. David Lapides talks with Dr. Martijn Wijburg about pharmacovigilance of patients treated with disease-modifying therapies for MS.
Dr. David Lapides discusses important ethical issues encountered in neurological clinical research with Dr. Benjamin Tolchin. Show references: https://n.neurology.org/content/94/15/661.abstract
In the first segment, Dr. Ted Burns talks with Drs. P. James B. Dyck and Shahar Shelly about clinical, neurophysiological, and pathological features of CISP-plus in comparison to CISP. In the second part of the podcast, Dr. David Lapides discusses important ethical issues encountered in neurological clinical research with Dr. Benjamin Tolchin.
In the first segment, Dr. David Lapides talks with Dr. Nicolas Collongues about pregnancy in patients with neuromyelitis optica spectrum disorder. In the second part of the podcast, Dr. Jason Crowell discusses racial and ethnic health disparities exacerbated by COVID-19 with Drs. Leo Lopez III and Louis Hart.
Dr. David Lapides speaks with Prof. Yvonne Latty about her personal experience of having a parent with Alzheimer's disease.
In the first segment, Dr. David Lapides speaks with Prof. Yvonne Latty about her personal experience of having a parent with Alzheimer disease. In the second part of the podcast, Dr. Stacey Clardy talks with Dr. Anthony Amato about bimagrumab in sporadic inclusion body myositis.
Dr. David Lapides discusses making the diagnosis of brain death with Dr. Panayiotis Varelas and the AAN’s draft practice recommendations available for public comment.
In the first segment, Dr. Jeff Ratliff talks with Dr. Wilson Abdo about prolonged unconsciousness in COVID-19. In the second part of the podcast, Dr. David Lapides discusses making the diagnosis of brain death with Dr. Panayiotis Varelas.
In the first segment, Dr. David Lapides talks with Dr. April Zehm about her Neurology: Clinical Practice paper regarding Framing Discussions on Palliative Care in Neurology. In the second part of the podcast, you’ll hear Dr. Lapides’ interview with Dr. David Perez on Diagnosing Functional Neurologic Disorders.
In the first segment, Dr. Jason Crowell talks with Dr. Jennifer Shum about her paper on neural correlates of sign language production. In the second part of the podcast, Dr. David Lapides speaks with Dr. Matthew Stuart Robbins on the Headache Quality Measurement Set.
In the first segment, Dr. Derek Bauer talks with Dr. Christoph Beier about his paper on predicting treatment response in generalized epilepsy. In the second part of the podcast, Dr. David Lapides speaks with Dr. Diego Kaski about his Brain article on dissociated motor learning in functional gait disorders. Read the article here: https://bit.ly/36JjFOP. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by completing the online Podcast quiz.
In the first segment, Dr. Jeff Burns speaks with Dr. Michael Weiner about his New York Times article on blood tests for Alzheimer’s disease. Read the NYT article here: https://nyti.ms/3cKheMW. Next, Dr. David Lapides talks with Dr. Martin Monti about his Neurology Journal paper on subcortical involvement in traumatic brain injury. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by completing the online Podcast quiz.
In the first segment, Dr. Jason Crowell continues his discussion with Dr. Sonia Vallabh on a profile of prion disease, in the second part of a 2-part interview. Next, Dr. David Lapides talks with Dr. Amit Bar-Or about his paper discussing vaccine response in patients with MS. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by completing the online Podcast quiz.
In the first segment, Dr. David Lapides talks with Dr. Terence O'Brien about his paper on mortality in patients with non-epileptic seizures. Next, Dr. Jeffrey Ratliff talks with Dr. Nico Dosenbach about plasticity of functionally connected motor networks. Read Dr. Dosenbach's paper in Neuron: https://www.sciencedirect.com/science/article/abs/pii/S0896627320303536?via%3Dihub. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
In the first segment, Dr. David Lapides talks with Dr. Tarunya Arun about her paper discussing diagnosis of neurosarcoidosis. In the second part of the podcast, Dr. Jeffrey Ratliff talks with Dr. Jeffrey Schweitzer about his NEJM paper discussing progenitor cells for Parkinson disease. Read the NEJM article here: https://bit.ly/2XjHvuc. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
In the first segment, you'll hear the second part of an interview on migraine between Dr. Jason Crowell and Dr. David Watson, focusing on special patient populations in management of migraine. In the second segment, Dr. David Lapides talks with Dr. Kimbra Kenney and Dr. Jessica Gill about their paper on NFL as a biomarker following traumatic brain injury. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Dr. David Lapides talks with Dr. Thomas Oxley about stroke as a presenting feature of COVID-19 in the young. Read Dr. Oxley's special report in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMc2009787. You can hear the full interview here: https://neurology.libsyn.com/website/special-report-dr-thomas-oxley-talk-about-stroke-with-covid-19-in-the-young
In the first segment, Dr. Teshamae Monteith talks with Dr. Scott Hirsch about treatment of adult ADHD. In the second segment, Dr. David Lapides talks with Dr. David Hwang about his Neurology paper on factors impacting surrogate decision makers for acute brain injury patients. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Dr. David Lapides talks with Dr. Thomas Oxley about stroke as a presenting feature of COVID-19 in the young. Read Dr. Oxley's special correspondence in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMc2009787. For a clearing house of neurology related information on the coronavirus go to AAN.com/COVID19 to stay up-to-date.
Dr. David Lapides talks with Dr. Scott Kim about ethics in the time of COVID-19. Read Dr. Kim's editorial in Neurology: https://n.neurology.org/content/early/2020/04/06/WNL.0000000000009520. For a clearing house of neurology related information on the coronavirus go to AAN.com/COVID19 to stay up-to-date.
This month’s Delayed Recall highlights 13 interviews on functional neurologic disorders from the series interviewer David Lapides conducted with Jon Stone for the Neurology Minute podcast. The episodes aired between September 2019 and March 2020. In this series, Jon Stone discusses who is susceptible to FNDs, diagnosis of nonepileptic spells, the myth of FND as psychological disorders with psychological origins, the various treatments available to patients with functional neurologic disorders, and other topics.
In the first segment, Dr. Jason Crowell speaks with Dr. John Noseworthy on his NEJM article on preserving the physician-patient relationship, which you can read here: https://www.nejm.org/doi/full/10.1056/NEJMsr1912662. In the second part of the podcast, Dr. David Lapides talks with Dr. Frederik Piehl about his Neurology paper discussing how blood neurofilament-light levels segregate treatment effects in patients with multiple sclerosis. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
In the first segment, Dr. David Lapides speaks with Dr. Michael Wilson and Dr. Ryan Schubert on their article in Nature Medicine, “Pan-viral serology implicates enteroviruses in acute flaccid myelitis,” which you can read here: https://www.nature.com/articles/s41591-019-0613-1. In the second part of the podcast, Dr. Halley Alexander talks with Dr. Emma Foster about her Neurology paper on her paper discussing that antiepileptic drugs are not independently associated with cognitive dysfunction. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Dr. David Lapides talks with Dr. Riley Bove about her Neurology: Neuroimmunology & Neuroinflammation paper, "Minimal Breastmilk Transfer of Rituximab, a Monoclonal Antibody used in Neurological Conditions."
In the first segment, Dr. David Lapides talks with Dr. Riley Bove about her Neurology: Neuroimmunology & Neuroinflammation paper on her paper on minimal breastmilk transfer of rituximab, a monoclonal antibody used in neurological conditions. In the second part of the podcast, Dr. Jason Crowell speaks with Denise Roland of the Wall Street Journal about her story on an obscure model driving down drug costs. You can read their paper in the Wall Street Journal here: https://www.wsj.com/articles/obscure-model-puts-a-price-on-good-healthand-drives-down-drug-costs-11572885123. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
In the first segment, Dr. Stacey Clardy talks with Dr. Robert Silbergleit and Dr. Jaideep Kapur about anticonvulsant medications for status epilepticus. In the second part of the podcast, Dr. David Lapides talks with Dr. Josep Dalmau and Dr. Francesc Graus about about the future of neuroimmunology and neuroinflammation. You can read Dr. Silbergleit and Dr. Kapur's paper in the New England Journal of Medicine here: https://www.nejm.org/doi/full/10.1056/NEJMoa1905795.
Dr. David Lapides talks with Dr. Francesc Graus about his paper, "Clinical Features of Seronegative, but CSF Antibody-Positive, Anti-NMDA Receptor Encephalitis" You can read the article here: https://nn.neurology.org/content/7/2/e659
Dr. Josep Dalmau discusses his article, "Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis" with Dr. David Lapides.
In the first segment, Dr. David Lapides talks with Dr. Josep Dalmau and Dr. Francesc Graus about their Neurology: Neuroimmunology & Neuroinflammation paper on clinical features of seronegative, but CSF antibody positive, anti-NMDA receptor encephalitis. In the second part of the podcast, Dr. Stacey Clardy talks with Dr. Ken Tyler about infectious encephalitis and arthropod-borne infections in 2019. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
In the twelfth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses who should treat patients with functional neurologic disorders.
In the first segment, Dr. Jason Crowell talks with Dr. Daniel Hartung about his qualitative study on drug prices for MS. In the second part of the podcast, Dr. David Lapides talks with Dr. Jesse Mez about the duration of American football play and chronic traumatic encephalopathy. You can read Dr. Mez’s paper in the Annals of Neurology: https://onlinelibrary.wiley.com/doi/10.1002/ana.25611. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
In the eleventh part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses the current research on functional neurologic disorders.
In the next part of a series on clinical diagnostic reasoning and associated common biases, Dr. David Lapides discusses representativeness error.
In the first segment, Dr. Michelle Mauermann talks with Dr. Mary Reilly about her paper on targeted, next-generation, sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. In the second part of the podcast, Dr. David Lapides talks with Dr. Christine Fulling about gut microbiota and brain signaling via the vagus nerve to affect brain and behavior.
In the next part of a series on clinical diagnostic reasoning and associated common biases, Dr. David Lapides discusses attribution error.
In the next part of a series on clinical diagnostic reasoning and associated common biases, Dr. David Lapides discusses affectiveerror.
In the first part of a series on clinical diagnostic reasoning and associated common biases, Dr. David Lapides discusses availability error.
In the tenth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses the various treatments available to patients with functional neurologic disorders.
In the ninth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses the documentation of findings and how to wrap up a patient visit when working with functional neurologic disorders.
In the first part of the podcast, Dr. David Lapides talks with Dr. Thomas Kilduff about his Science report article reporting that REM sleep–active MCH neurons are involved in forgetting hippocampus-dependent memories, which you can read here: https://science.sciencemag.org/content/365/6459/1308. In the second segment, Dr. Stacey Clardy talks with Dr. Sylvia Tenembaum about her paper on prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination.
In the eighth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses the common pitfalls that occur in conversation with a patient when making a diagnosis of a FND.
In the first segment, Dr. David Lapides talks with Dr. Allan Ropper about NEJM paper on neurosyphilis, which you can read here: https://www.nejm.org/doi/full/10.1056/NEJMx190030. In the second segment, Dr. Jeffrey Ratliff talks with Dr. Christopher Tarolli about his Neurology: Clinical Practice paper on symptom burden among individuals with Parkinson disease. In the second part of the podcast.
In the seventh part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses the myth of FND as psychological disorders with psychological origins.
In the sixth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses how to discuss FND diagnosis with patients in clinic.
In the fifth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses differentiating FNDs and malingering symptoms in patients.
Dr. David Lapides discusses depression in multiple sclerosis.
Dr. David Lapides talks about Gaba A + B receptor encephalitis.
Dr. David Lapides discusses a Neurology: Neuroimmunology & Neuroinflammation review of IGG4 hypertrophic pachymeningitis from the July 2019 issue.
In the fourth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses diagnosis of nonepileptic spells.
In the third part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses diagnosis of functional movement disorders.
In the first segment, Dr. David Lapides talks with Dr. Bernard Hemmer about his paper on a large case-control study on vaccination as risk factor of multiple sclerosis. In the second part of the podcast, Dr. Stacey Clardy focuses her discussion with Dr. Amanda Grennell on an update on Zika for 2019. Read the full article here: https://www.nature.com/articles/d41586-019-01906-z. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Dr. David Lapides discusses management of measles vaccination in immuno-suppressed patients.
Dr. David Lapides discusses the importance of early antibody evaluation in the setting of a new case of optic neuritis.
Dr. David Lapides discusses a recent Minnesota Supreme Court decision that a patient-doctor relationship was not a necessary element of a claim for professional negligence.
In the first segment, Dr. Stacey Clardy talks with Dr. P. James B. Dyck about his paper on the incidence of lumbrosacral radiculoplexus neuropathy and association with diabetes mellitus. In the second segment, Dr. David Lapides talks with Dr. Teshamae Monteith about the use of CGRP monoclonal antibodies for migraine prevention.
In the first segment, Dr. David Lapides talks with Dr. C.N. van Ettekoven about the Four Score as a predictor of outcome in adults with bacterial meningitis, from the May 28th issue. In the second part of the podcast, Dr. Jason Crowell focuses his talk with Dr. Deborah Dowell on her NEJM perspective article looking at opioid prescribing and response to the CDC guidelines. You can read Dr. Dowell’s paper here: https://www.nejm.org/doi/full/10.1056/NEJMp1904190. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Dr. David Lapides discusses cerebrospinal fluid analysis in the diagnosis of autoimmune encephalitis.
Dr. David Lapides covers Sjogren's Syndrome-related trigeminal neuralgia.
This month’s Delayed Recall highlights episodes on autoimmune neurology. Dr. David Lapides and Dr. Maarten Titulaer start the show discussing the long-term neuropsychological outcome following pediatric anti-nmdar encephalitis, which first aired on May 29th, 2018. The next segment, from January 15th, has Dr. Lapides and Dr. Balu focusing on a score that predicts one year functional status in anti-NMDA receptor encephalitis patients. Following this segment is one from October 23rd and finds Dr. Stacey Clardy talking to Dr. Andrew McKeon about his paper on paraneoplastic neuronal intermediate filament autoimmunity. This episode concludes with an interview on a Neurology: Neuroimmunology & Neuroinflammation paper on IgLON5 autoimmunity between Dr. Stacey Clardy and Dr. Andrew McKeon from March 27th, 2018.
1. A score that predicts one year functional status in anti-NMDA receptor encephalitis patients. 2. [What's Trending]: Part 2: Drug pricing and the Institute for Clinical and Economic Review framework. In the first segment, Dr. David Lapides talks with Dr. Ramani Balu about his paper on a score that predicts one year functional status in anti-NMDA receptor encephalitis patients. In the second part of the podcast, you'll hear the the second part of Dr. Gordon Smith's interview with Dr. Steve Pearson on the Institute for Clinical and Economic Review and drug pricing. DISCLOSURES: Dr. David Lapides has served as a consultant for Board Vitals; and has received foundation/society research support from the National Multiple Sclerosis Society Clinical Fellowship. Dr. Ramani Balu has received governmental research support from the National Institutes of Health and the Department of Defense. Dr. A. Gordon Smith has served on the scientific advisory board of the Regenesis Data Monitoring Committee; has served on the editorial boards for Continuum and Annals of Clinical and Translational Neurology; has served as a consultant for Regenesis; has served on the speakers' bureau for Alexion; has received commercial research support from Impeto Medical SAS; and has received governmental research support from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Neurological Disorders and Stroke. Dr. Steve Pearson's Institute for Clinical and Economic Review has received membership dues from Aetna, Alnylam, America’s Health Insurance Plans (AHIP), Anthem, AstraZeneca, Blue Shield of CA, Cambia Health Solution, CVS, Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation (HCSC), HealthPartners, Johnson & Johnson, Kaiser Permanente, Mallinckrodt Pharmaceuticals, Merck & Co., National Pharmaceutical Council (NPC), Novartis, Premera Blue Cross, Prime Therapeutics, Regeneron, Sanofi, and United Healthcare; and has received foundation/society research support from the Laura and John Arnold Foundation, the California Health Care Foundation, Blue Shield of California Foundation, Kaiser, East Bay Community Foundation, and the Commonwealth Fund.
1. Gray matter differences in patients with functional movement disorders 2. [What’s Trending]: Recovery of Over-Ground Walking after Chronic Motor Complete Spinal Cord Injury. In the first segment, Dr. David Lapides talks with Dr. Carine Maurer about her paper on gray matter differences in patients with functional movement disorders. In the second part of the podcast, Dr. Alex Menze focuses his interview with Claudia Angeli on recovery of over-ground walking after chronic motor complete spinal cord injury. Dr. David Lapides reports no disclosures. Dr. Carine Maurer received research support from NIH, Intramural Research Program and academic research support from Stony Brook University School of Medicine. Dr. Maurer has done consultancy work for Gerson Lehrman Group. Dr. Alex Menze reports no disclosures. Dr. Claudia Angeli reports no disclosures.
This month’s Delayed Recall features the Lesson of the Week series on functional disorders with Dr. David Lapides interviewing Dr. Jon Stone. The first interview provides an overview of functional disorders; next is a discussion of diagnostic approaches. The third segment highlights how to deliver a functional disorder diagnosis to a patient, and the final interview discusses treatment management. All these interviews were originally published in June and July 2018.
1. Featured Article: Practice guideline update summary: Efficacy and tolerability of new antiepileptic drugs I: Treatment of new-onset epilepsy2. Lesson of the Week: Functional Disorders This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 10, 2018 issue of Neurology. In the first segment, Dr. Derek Bauer talks with Dr. Jacqueline French about her paper, a summary of a recent practice guideline on the treatment of new-onset epilepsy. In the second part of the podcast, Dr. David Lapides continues the Lesson of the Week discussion on functional disorders with Dr. Jon Stone. DISCLOSURES: Dr. French has served on scientific advisory boards and consulted for the Epilepsy Foundation, Acadia, Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cavion, Cerecor, Cerebral Therapeutics, Concert Pharmaceuticals, Covance, CuroNZ, Eisai, Empatica, Engage, Georgia Regents University, Glaxo Smith-Kline, GW Pharma, J&J Pharmaceuticals, Marinus, MonosolRx, Monteris, Nestle-Health Science, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Pfizer-Neusentis, Sage Therapeutics, Shire, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Ultragenyx, Xenon Pharmaceuticals, Xeris, Zogenix and Zynerba; has received research support from Alexza, Acorda, LCGH, Eisai Medical Research, LCGH, Lundbeck, Neurelis, Pfizer, SK life sciences, Sunovion, Takeda, UCB, Upsher-Smith, Biogen, NINDS (2U01NS038455-11A1), Epilepsy Foundation, and Epilepsy Study Consortium; has received paid travel to present findings at scientific meetings, present at investigators' meetings, attend advisory boards, or give lectures from Epilepsy Study Consortium, Epilepsy Foundation, International League Against Epilepsy, American Academy of Neurology, American Epilepsy Foundation, Adamas, Biogen, Eisai, Engage, GW Pharma, GSK, Novartis, Otsuka, Ovid, Pfizer, Sage, Sunovion, Takeda, UCB, Ultragenyx, Upsher-Smith, Zynerba, Blackfynn Pfizer, Pfizer-Neusentis, Sage, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith,Zogenix, and Zynerba; serves on editorial boards for Lancet Neurology, Neurology Today, and Epilepsy Currents; and serves as President, Epilepsy Study Consortium Chief Scientific Officer, Epilepsy Foundation. Drs. Bauer and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
1. Featured Article: Conscious sedation or local anesthesia during endovascular treatment for acute ischemic stroke2. Lesson of the Week: Functional disordersThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 3, 2018, print issue of Neurology. In the first segment, Dr. Brian Eckerle talks with Dr. Rob van de Graaf about his paper on conscious sedation vs local anesthesia during endovascular treatment for ischemic stroke. For the Lesson of the Week segment, Dr. David Lapides and Dr. Jon Stone continue their discussion of functional disorders. DISCLOSURES: Drs. Eckerle, van de Graaf, and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
1. Featured Neurology® Clinical Practice Article: Reflections on Translation: Views of Participants in a Multi-Site Canadian CCSVI Clinical Trial2. Lesson of the Week: Functional disorders This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 12, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Shelly Benjaminy about her paper on patients’ perspectives from the chronic cerebrospinal venous insufficiency clinical trial in Canada. In the second segment, Dr. David Lapides continues his discussion with Dr. Jon Stone about how to approach functional disorders.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Benjaminy has received research support from Canadian Institutes of Health Research [INV-126709], University of British Columbia [Public Scholars Award, Li Tze Fong Memorial Fellowship, Millie and Ralph Drabinsky Graduate Scholarship in Medicine, and Faculty of Medicine Graduate Scholarship], and Stem Cell Network Canada. Dr. Lapides reports no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
1. Featured Article: Validation of a simple disease-specific quality of life measure for diabetic polyneuropathy; the CAPPRI2. Lesson of the Week: Functional disorders This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 5, 2018, print issue of Neurology. In the first segment, Dr. Alex Menze interviews Dr. Kelly Gwathmey about her paper on a new quality of life measure for diabetic polyneuropathy. For the second segment, Dr. David Lapides speaks with Dr. Jon Stone about updates in approaching functional disorders in the clinic.DISCLOSURES: Dr. Menze, Dr. Gwathmey, and Dr. Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.
1. Featured Article: Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis2.What's Trending: Amateur fundus photographyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 29, 2018 issue of Neurology. In the first segment, Dr. David Lapides talks with Dr. Maarten Titulaer about his paper on long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis. Next, Dr. Roy Strowd talks with Dr. Saman Zafar about her paper on amateur fundus photography for our “What’s Trending” feature of the week. DISCLOSURES: Dr. Titulaer serves on the editorial board of Neurology: Neuroimmunology & Neuroinflammation; filed a patent for "methods for typing neurological disorders and cancer, and devices for use therein" specifically about diagnostics for anti-GABAB receptor antibodies and KCTD antibodies; and has received research support from Medimmune LLC, Guidepoint Global LLC, Novartis, Euroimmun AG, the Netherlands Organisation for Scientific Research, an ErasmusMC fellowship, and the Dutch Epilepsy Foundations. Dr. Strowd serves on the editorial board for Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology. Dr. Lapides and Dr. Zafar report no disclosures.
1) Neurology® Clinical Practice: Alice in Wonderland syndrome: a systematic review2) What's Trending: Interview with Clinton Wright about his paper on leisure time physical activity and how it is associated with cognitive decline3) Topic of the month: Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndromeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Lapides interviews Dr. Jan Dirk Blom about his Neurology: Clinical Practice paper on the Alice in Wonderland syndrome. Dr. Ted Burns is interviewing Dr. Clinton Wright for our “What's Trending” feature of the week about his paper on leisure time physical activity and how it is associated with cognitive decline. Dr. Alberto Espay interviews Dr. Jeremy Schmahmann about his Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome.DISCLOSURES: Dr. Blom receives royalties from the publication of the book Hallucinations, Research and Practice and the book A Dictionary of Hallucinations.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Wright receives royalties from UpToDate website for two chapters on vascular dementia; receives research support from American Stroke Association-Bugher Foundation Centers of Excellence project and the NIH.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as aneditorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Schmahmann serves as an editorial board member of The Cerebellum and its sister journal, Cerebellum and Ataxias; serves on the scientific advisory board for Ataxion, Inc. and Atlas Ventures; Receives royalties from the publications of the books: The Cerebellum and Cognition: International Review of Neurobiology, MRI Atlas of the Human Cerebellum, Pathways of the Brain, Cerebellar Disorders in Children: Clinics in Development Medicine, and Handbook of the Cerebellum and Cerebellar Disorders; is a consultant for Takeda Pharmaceutical Company Limited; holds stock option in Ataxion, Inc. and Atlas Ventures; receives research support from Birmingham Foundation, MINDlink Foundation, Sidney R. Baer Jr., Foundation, National Ataxia Foundation, Ataxia Telangiectasia Children's Project and the NIH.NO CME WILL BE OFFERED THIS WEEK.